CJC-1295 vs Sermorelin
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: CJC-1295 DAC, CJC-1295 no DAC
A synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates GH release from the pituitary. Often combined with a GHRP like Ipamorelin for synergistic effects.
Also: Geref, GRF 1-29
A truncated analog of natural GHRH containing the first 29 amino acids. Previously FDA-approved for pediatric GH deficiency, now used off-label for adult hormone optimization.
Key Comparison Insights
- Both peptides belong to the Growth Hormone category, suggesting similar primary applications.
- CJC-1295 has stronger research evidence (Human Trials) compared to Sermorelin (Animal Studies).
Detailed Comparison
| Attribute | CJC-1295 | Sermorelin |
|---|---|---|
| Category | Growth Hormone | Growth Hormone |
| FDA Status | Not FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | CJC-1295 binds to GHRH receptors on the pituitary, stimulating GH synthesis and release. The DAC (Drug Affinity Complex) version binds to albumin, extending half-life to 6-8 days. Without DAC (Mod GRF 1-29), half-life is about 30 minutes. | Sermorelin is bioidentical to the active portion of endogenous GHRH. It stimulates the pituitary's natural production and release of growth hormone, maintaining normal feedback mechanisms and pulsatile GH release patterns. |
| Common Dosing | 100 mcg daily (no DAC) or 2 mg weekly (with DAC) Daily (no DAC) or 1-2x weekly (with DAC) | 200-500 mcg before bed Once daily, typically before bed |
| Administration | Subcutaneous injection | Subcutaneous injection at bedtime |
| Typical Duration | 8-12 weeks | 3-6 months typical |
| Best Time to Take | Before bed | Before bed (fasted) |
Possible Side Effects May vary by individual |
|
|
| Research Summary | Phase II trial in HIV lipodystrophy patients was discontinued after a patient death (MI, deemed unrelated but trial ended as precaution). Earlier studies show sustained 2-10 fold increase in GH and IGF-1 levels with good tolerability at doses up to 60 mcg/kg. | Extensive clinical research from FDA approval process. Studies demonstrate restoration of youthful GH levels, improved sleep quality, increased lean body mass, and enhanced recovery. Generally preserves natural GH axis better than exogenous GH. |
Frequently Asked Questions: CJC-1295 vs Sermorelin
What is the difference between CJC-1295 and Sermorelin?
CJC-1295 is a growth hormone peptide that a synthetic analog of growth hormone-releasing hormone (ghrh) that stimulates gh release from the pituitary. often combined with a ghrp like ipamorelin for synergistic effects. Sermorelin is a growth hormone peptide that a truncated analog of natural ghrh containing the first 29 amino acids. previously fda-approved for pediatric gh deficiency, now used off-label for adult hormone optimization. The main differences lie in their mechanisms of action and clinical applications.
Which is better, CJC-1295 or Sermorelin?
Neither is universally "better" - the choice depends on your specific goals. CJC-1295 is typically used for growth hormone purposes, while Sermorelin is used for growth hormone. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can CJC-1295 and Sermorelin be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using CJC-1295 and Sermorelin together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.